Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
grade C 2.19 2.34% 0.05
AEZS closed up 0.94 percent on Friday, June 15, 2018, on 49 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical AEZS trend table...

Date Alert Name Type % Chg
Jun 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.34%
Jun 15 Narrow Range Bar Range Contraction 2.34%
Jun 15 Wide Bands Range Expansion 2.34%
Jun 14 Narrow Range Bar Range Contraction 3.30%
Jun 14 Wide Bands Range Expansion 3.30%
Jun 13 Wide Bands Range Expansion 1.86%
Jun 12 Narrow Range Bar Range Contraction -1.35%
Jun 12 NR7 Range Contraction -1.35%
Jun 12 Wide Bands Range Expansion -1.35%
Jun 12 Up 3 Days in a Row Strength -1.35%

Older signals for AEZS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.29
52 Week Low 0.89
Average Volume 209,569
200-Day Moving Average 1.9595
50-Day Moving Average 1.8436
20-Day Moving Average 2.1623
10-Day Moving Average 2.1545
Average True Range 0.1455
ADX 27.8
+DI 24.51
-DI 22.55
Chandelier Exit (Long, 3 ATRs ) 2.2135
Chandelier Exit (Short, 3 ATRs ) 2.2365
Upper Bollinger Band 2.5238
Lower Bollinger Band 1.8008
Percent B (%b) 0.47
BandWidth 33.436618
MACD Line 0.0804
MACD Signal Line 0.11
MACD Histogram -0.0296
Fundamentals Value
Market Cap 34.48 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -1.25
Price-to-Sales 28.12
Price-to-Book 6.12
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.25
Resistance 3 (R3) 2.24 2.19 2.23
Resistance 2 (R2) 2.19 2.17 2.20 2.22
Resistance 1 (R1) 2.17 2.15 2.18 2.18 2.22
Pivot Point 2.12 2.12 2.13 2.13 2.12
Support 1 (S1) 2.10 2.10 2.11 2.11 2.06
Support 2 (S2) 2.05 2.08 2.06 2.06
Support 3 (S3) 2.03 2.05 2.05
Support 4 (S4) 2.04